We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Fecal Immunochemical Test Assessed in Suspected Colorectal Cancer

By LabMedica International staff writers
Posted on 05 Nov 2020
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). More...
Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.

The fecal immunochemical test (FIT) detects the globin component of hemoglobin (Hb) by immunoassay and can reliably measure the fecal Hb concentration (f-Hb) to the nearest microgram of Hb per gram of faces (µg/g). Since 2010, over 25 diagnostic accuracy studies have reported data on the use of FIT in symptomatic patients utilizing a range of cut-offs.

A team of medical scientists led by those at Croydon University Hospital (Croydon, UK) analyzed almost 10,000 patients referred to a specialist for suspected CRC symptoms that met criteria for urgent care. FIT sensitivity was maximized to 97.0% at the lowest fecal hemoglobin concentration cutoff of 2 µg/g. Between October 2017 and December 2019, 21,126 patients were sent recruitment packs, 13,219 (62.6%) returned FIT devices. Complete FIT and colonoscopy outcomes were available for 9,822 patients, who were included in the study results. Median age was 65 in the final cohort of kit-returning patients, 54% of whom were women.

FIT analysis was performed at one centralized laboratory where staff were blinded to patient clinical information. The HM-JACKarc analytical system (Hitachi Chemical Diagnostics Systems, Tokyo, Japan) was used to analyze all samples. The analytical working range is 7–400 µg/g. The limit of detection (LoD) of the assay is 2 µg/g and the limit of quantitation is 7 µg/g. The National Institute for Health and Care Excellence (NICE) recommended an f-Hb cut-off of 10 µg/g in the DG30 guidelines. Colonoscopy was chosen as the reference standard since it is acknowledged to be the gold-standard investigation for colorectal disease. Colonoscopists were blinded to the FIT results.

The team reported that incidence of CRC at colonoscopy was 3.3%. At fecal hemoglobin concentration cutoffs of 2, 10, and 150 µg/g, FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively. The positive predictive values of FIT for CRC was 8.7% at the 2 µg/g cutoff, 16.1% at the 10 µg/g cutoff, and 31.1% at the 150 µg/g cutoff. Respective negative predictive values were 99.8%, 99.6%, and 98.9%. In terms of sensitivity for CRC, this decreased from 97.0% at the 2 µg/g cutoff, to 90.9% at the 10 µg/g cutoff, and 70.8% at the 150 µg/g cutoff. Specificity increased from 64.9% to 83.5% and 94.6%, respectively.

The authors concluded that a higher hemoglobin cutoff could be set to match capacity in resource-limited settings, which would reduce the number of positive results, onwards referral for investigation and demand for colonoscopy but at the expense of detecting fewer cancers. The study was published on October 21. 2020 in the journal GUT.

Related Links:
Croydon University Hospital
Hitachi Chemical Diagnostics Systems



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.